Direxion Daily Small Cap Bull 3X ETF

MicroSectors Gold Miners 3X Leveraged ETN

Bank Of Montreal

ProShares UltraPro Dow30

Direxion Daily Gold Miners Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Bl 3X ETF

Direxion Daily Semicondct Bull 3X ETF

Guggenheim Solar ETF

Direxion Daily S&P500 Bull 3X ETF

ProShares UltraPro S&P500

Direxion Daily Small Cap Bear 3X ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Gold Miners Bear 3X ETF

Direxion Daily S&P 500 Bear 3X ETF

Direxion Technology Bear 3X Shares

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bear 3X ETF

QuantumScape Corporation Class A Common Stock

Nike Inc. Common Stock

Hims & Hers Health Inc. Class A Common Stock

Dick's Sporting Goods Inc Common Stock

Freeport-McMoRan Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Arista Networks Inc. Common Stock

Spotify Technology S.A. Ordinary Shares

Cleveland-Cliffs Inc. Common Stock

C3.ai Inc. Class A Common Stock

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Hyatt Hotels Corporation Class A Common Stock

Trex Company Inc. Common Stock

PNC Financial Services Group Inc. (The) Common Stock

Unity Software Inc. Common Stock

Abbott Laboratories Common Stock

Carvana Co. Class A Common Stock

Luxfer Holdings PLC Ordinary Shares

CVR Energy Inc. Common Stock

Chipotle Mexican Grill Inc. Common Stock

Click here to get full coverage on Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments  PR Newswire

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire

Click here to get full coverage on Biohaven stock slides as FDA delays drug review (BHVN:NYSE) - Seeking Alpha

Biohaven stock slides as FDA delays drug review (BHVN:NYSE)  Seeking Alpha

Biohaven stock slides as FDA delays drug review (BHVN:NYSE) - Seeking Alpha

Click here to get full coverage on Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated - Stock Titan

Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated  Stock Titan

Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated - Stock Titan

Click here to get full coverage on Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey

Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy”  Insider Monkey

Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey

Click here to get full coverage on Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - Yahoo Finance

Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy  Yahoo Finance

Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - Yahoo Finance

Click here to get full coverage on BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More  Nasdaq

BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results  PR Newswire

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Click here to get full coverage on TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider

TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN'  StreetInsider

TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider

Click here to get full coverage on Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 - Yahoo Finance

Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025  Yahoo Finance

Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 - Yahoo Finance

Click here to get full coverage on Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial - Seeking Alpha

Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial  Seeking Alpha

Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial - Seeking Alpha

Click here to get full coverage on Noteworthy Friday Option Activity: BHVN, TDUP, PAYX - Nasdaq

Noteworthy Friday Option Activity: BHVN, TDUP, PAYX  Nasdaq

Noteworthy Friday Option Activity: BHVN, TDUP, PAYX - Nasdaq

Click here to get full coverage on Breakthrough Parkinson's Treatment: Biohaven's Novel Brain Drug Enters Pivotal Trial for 10M Patients - Stock Titan

Breakthrough Parkinson's Treatment: Biohaven's Novel Brain Drug Enters Pivotal Trial for 10M Patients  Stock Titan

Breakthrough Parkinson's Treatment: Biohaven's Novel Brain Drug Enters Pivotal Trial for 10M Patients - Stock Titan

Click here to get full coverage on Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - PR Newswire

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class  PR Newswire

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - PR Newswire

Click here to get full coverage on Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - PR Newswire

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting  PR Newswire

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - PR Newswire

Click here to get full coverage on Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia  PR Newswire

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire

Click here to get full coverage on Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300  PR Newswire

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire

Click here to get full coverage on Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PR Newswire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares  PR Newswire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PR Newswire

Click here to get full coverage on Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates  PR Newswire

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire

Click here to get full coverage on Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio  PR Newswire

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire

Click here to get full coverage on Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire

Biohaven Announces Proposed Public Offering of Common Shares  PR Newswire

Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire

Click here to get full coverage on Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News - GuruFocus

Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News  GuruFocus

Biohaven (BHVN) Price Target Lowered by JPMorgan to $55 | BHVN Stock News - GuruFocus

Click here to get full coverage on Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital - StreetInsider

Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital  StreetInsider

Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital - StreetInsider

Click here to get full coverage on How To Trade (BHVN) - news.stocktradersdaily.com

How To Trade (BHVN)  news.stocktradersdaily.com

How To Trade (BHVN) - news.stocktradersdaily.com

Click here to get full coverage on Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News - GuruFocus

Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News  GuruFocus

Biohaven (BHVN) Target Price Lowered by JP Morgan Analyst | BHVN Stock News - GuruFocus

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN - PR Newswire

Click here to get full coverage on Biohaven Pharma (BHVN) Misses Q1 EPS by 47c - StreetInsider

Biohaven Pharma (BHVN) Misses Q1 EPS by 47c  StreetInsider

Biohaven Pharma (BHVN) Misses Q1 EPS by 47c - StreetInsider

Click here to get full coverage on First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven - Stock Titan

First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven  Stock Titan

First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven - Stock Titan

Click here to get full coverage on Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine - Stock Titan

Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine  Stock Titan

Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine - Stock Titan

Click here to get full coverage on (BHVN) Investment Analysis and Advice - news.stocktradersdaily.com

(BHVN) Investment Analysis and Advice  news.stocktradersdaily.com

(BHVN) Investment Analysis and Advice - news.stocktradersdaily.com

Click here to get full coverage on Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity  PR Newswire

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire

Click here to get full coverage on Independent Director of Biohaven John Childs Buys More Stock - simplywall.st

Independent Director of Biohaven John Childs Buys More Stock  simplywall.st

Independent Director of Biohaven John Childs Buys More Stock - simplywall.st

Click here to get full coverage on BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - PR Newswire

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm  PR Newswire

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - PR Newswire

Click here to get full coverage on Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Insider Monkey

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21  Insider Monkey

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Insider Monkey

Click here to get full coverage on Notable Thursday Option Activity: CELH, AMD, BHVN - Nasdaq

Notable Thursday Option Activity: CELH, AMD, BHVN  Nasdaq

Notable Thursday Option Activity: CELH, AMD, BHVN - Nasdaq

Click here to get full coverage on Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts?  Insider Monkey

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey

Click here to get full coverage on Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News - GuruFocus

Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News  GuruFocus

Biohaven (BHVN) Teams Up with Bexorg for CNS Disorder Research Collaboration | BHVN Stock News - GuruFocus

Click here to get full coverage on Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha

Biohaven's Exciting Year Of Catalysts (NYSE:BHVN)  Seeking Alpha

Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on (BHVN) Long Term Investment Analysis - news.stocktradersdaily.com

(BHVN) Long Term Investment Analysis  news.stocktradersdaily.com

(BHVN) Long Term Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus

Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News  GuruFocus

Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus

Click here to get full coverage on Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN)  Seeking Alpha

Biohaven: Highly Priced Biotech With Broad Pipeline But No Revenues (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Why Biohaven (BHVN) Stock Is Rallying Today - Insider Monkey

Why Biohaven (BHVN) Stock Is Rallying Today  Insider Monkey

Why Biohaven (BHVN) Stock Is Rallying Today - Insider Monkey

Click here to get full coverage on Why Biohaven Stock Plummeted by More Than 15% Today - The Motley Fool

Why Biohaven Stock Plummeted by More Than 15% Today  The Motley Fool

Why Biohaven Stock Plummeted by More Than 15% Today - The Motley Fool

Click here to get full coverage on (BHVN) Proactive Strategies - news.stocktradersdaily.com

(BHVN) Proactive Strategies  news.stocktradersdaily.com

(BHVN) Proactive Strategies - news.stocktradersdaily.com

Click here to get full coverage on Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline - GuruFocus

Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline  GuruFocus

Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline - GuruFocus

Click here to get full coverage on Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts - Insider Monkey

Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts  Insider Monkey

Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts - Insider Monkey

Click here to get full coverage on Where are the Opportunities in (BHVN) - news.stocktradersdaily.com

Where are the Opportunities in (BHVN)  news.stocktradersdaily.com

Where are the Opportunities in (BHVN) - news.stocktradersdaily.com

Click here to get full coverage on Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Developments | BHVN Stock News - GuruFocus

Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Developments | BHVN Stock News  GuruFocus

Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Developments | BHVN Stock News - GuruFocus

Click here to get full coverage on Biohaven Pharma (BHVN) Misses Q4 EPS by 11c - StreetInsider

Biohaven Pharma (BHVN) Misses Q4 EPS by 11c  StreetInsider

Biohaven Pharma (BHVN) Misses Q4 EPS by 11c - StreetInsider

Click here to get full coverage on Breakthrough IgA Nephropathy Treatment Achieves 81% Disease Marker Reduction in First-in-Class Trial - Stock Titan

Breakthrough IgA Nephropathy Treatment Achieves 81% Disease Marker Reduction in First-in-Class Trial  Stock Titan

Breakthrough IgA Nephropathy Treatment Achieves 81% Disease Marker Reduction in First-in-Class Trial - Stock Titan

Click here to get full coverage on Biohaven (BHVN) Advances Innovative Drug Trials for Immune Diseases | BHVN Stock News - GuruFocus

Biohaven (BHVN) Advances Innovative Drug Trials for Immune Diseases | BHVN Stock News  GuruFocus

Biohaven (BHVN) Advances Innovative Drug Trials for Immune Diseases | BHVN Stock News - GuruFocus

Click here to get full coverage on Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?  Yahoo Finance

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance

Click here to get full coverage on Why Biohaven Stock Dove by Nearly 20% on Thursday - The Motley Fool

Why Biohaven Stock Dove by Nearly 20% on Thursday  The Motley Fool

Why Biohaven Stock Dove by Nearly 20% on Thursday - The Motley Fool

Click here to get full coverage on Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - MarketScreener

Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49  MarketScreener

Earnings Flash (BHVN) BIOHAVEN LTD. Posts Q4 Loss $-1.71 Per Share, vs. FactSet Est of $-1.49 - MarketScreener

Click here to get full coverage on Manoj Bhavan restaurant opens in Mylapore. Breakfast combo offer – for Rs.89 - MYLAPORE TIMES -

Manoj Bhavan restaurant opens in Mylapore. Breakfast combo offer – for Rs.89  MYLAPORE TIMES -

Manoj Bhavan restaurant opens in Mylapore. Breakfast combo offer – for Rs.89 - MYLAPORE TIMES -

Click here to get full coverage on President Droupadi Murmu watches Aamir Khan's ‘Sitaare Zameen Par’ at Rashtrapati Bhavan - Deccan Herald

President Droupadi Murmu watches Aamir Khan's ‘Sitaare Zameen Par’ at Rashtrapati Bhavan  Deccan Herald

Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Price Chart

Key Statistics

Technicals

About BHVN

Latest News

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire

Biohaven stock slides as FDA delays drug review (BHVN:NYSE) - Seeking Alpha

Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated - Stock Titan

Advanced Charts

Top Gainers

Top Losers